Uninterrupted Direct-acting Oral Anticoagulation in Patients Undergoing Transradial Percutaneous Coronary Procedures

• Status: Recruiting
• Trial end date: 2023-08-20
• Target enrollment: 0
• Participant gender: All

Summary

Up to 20-30% of patients who are candidates for direct oral anticoagulation (DOAC) present with concomitant ischemic heart disease and often require coronary angiography with or without percutaneous coronary intervention (PCI). The decision whether to continue the DOAC throughout periprocedural period or interrupt DOAC before planned procedure represents a substantial challenge in daily clinical practice.

The objective of this study is to evaluate the safety of uninterrupted direct-acting oral anticoagulation in patients undergoing trans-radial percutaneous coronary procedures.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hospital Universitario La Fe

Criteria

Inclusion Criteria:

• Patients under anticoagulation with DOAC and any indication for diagnostic or therapeutic trans-radial percutaneous coronary procedures. At least 50% of the population undergoing PCI will be included.

Exclusion Criteria:

1. Aged < 18 years

2. Cardiogenic shock

3. Major active bleeding at the time of the procedure

4. Use of mechanical circulatory support

5. Chronic total occlusions

6. Pre-planned vascular access different from radial artery access (i.e. femoral, brachial, ulnar)

7. Inability to provide informed consent

8. Unable to understand and follow study-related instructions or unable to comply with study protocol

9. Currently participating in another trial

10. Pregnant women